scispace - formally typeset
S

Serge Muyldermans

Researcher at Vrije Universiteit Brussel

Publications -  323
Citations -  30516

Serge Muyldermans is an academic researcher from Vrije Universiteit Brussel. The author has contributed to research in topics: Single-domain antibody & Antibody. The author has an hindex of 80, co-authored 305 publications receiving 26561 citations. Previous affiliations of Serge Muyldermans include Dalian University of Technology & Université libre de Bruxelles.

Papers
More filters
Journal ArticleDOI

Emergence and evolution of functional heavy-chain antibodies in Camelidae

TL;DR: This review focuses on the dedicated immunoglobulin (Ig) genes that encode the HCAb in Camelidae (camels, dromedaries and llamas), about their origin, and how these camel Immunoglobulins evolved and acquire a large and diverse repertoire of antigen binding sites in absence of the H-L combinatorial diversity.
Journal ArticleDOI

Antibody Fragments as Probe in Biosensor Development

TL;DR: In this article, multiple approaches to specifically orient and couple antibody fragments in a generic one-step procedure directly on a biosensor substrate are discussed, including the size of the probe and other issues like choice of immobilization tag, type of solid support and probe stability.
Journal ArticleDOI

A Case Of Convergence: Why Did a Simple Alternative to Canonical Antibodies Arise in Sharks and Camels?

TL;DR: It was demonstrated that HCAbs from dromedaries (one-humped camels) infected with trypanosomes are capable of associating tightly and specifically with these parasite antigens, and even more peculiar, the HCABS function alongside conventional H2L2 antibodies.

New Methods in Cardiovascular Biology Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions

TL;DR: The 99mTc-labeled, anti-VCAM1 nanobody cAbVCAM 1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity, demonstrating the potential of nanobodies as a new class of radiotracers for cardiovascular applications.
Journal ArticleDOI

VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'.

TL;DR: It is clear that in the near future Nanobodies will be at the core of novel serotherapeutics as they combine multiple benefits over other reagents to treat scorpion envenomed patients.